Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-09-05
2006-09-05
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S492000
Reexamination Certificate
active
07101871
ABSTRACT:
The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
REFERENCES:
patent: 5939560 (1999-08-01), Jenkins et al.
patent: 6011155 (2000-01-01), Villhauer
patent: 6166063 (2000-12-01), Villhauer
patent: 6303661 (2001-10-01), Demuth et al.
patent: 6432969 (2002-08-01), Villhauer
patent: 6699871 (2004-03-01), Edmondson et al.
patent: WO 97/40832 (1997-11-01), None
patent: WO 98/19998 (1998-05-01), None
patent: WO 98/19998 (1998-05-01), None
patent: WO 00/34241 (2000-06-01), None
patent: WO 01/34594 (2001-05-01), None
patent: WO 01/96295 (2001-12-01), None
patent: WO 01/96295 (2001-12-01), None
patent: WO 02/02560 (2002-01-01), None
patent: WO 02/076450 (2002-10-01), None
patent: WO 03/000180 (2003-01-01), None
patent: WO 03/000181 (2003-01-01), None
patent: WO 03/000181 (2003-01-01), None
patent: WO 03/082817 (2003-10-01), None
patent: WO 2004/007468 (2004-01-01), None
patent: WO 2004/032836 (2004-04-01), None
patent: WO 2004/050022 (2004-06-01), None
patent: WO 2004/058266 (2004-07-01), None
patent: WO 2004/064778 (2004-08-01), None
patent: WO 2004/069162 (2004-08-01), None
J. J. Holst, “Treatment of Type 2 Diabetes Mellitus with Agonists of the GLP-1 Receptor or DPP-IV Inhibitors”, Expert Opin. Emerg. Drugs, vol. 9(1) pp. 155-166, 2004.
C. F. Deacon, et al., “Inhibitors of dipeptidyl peptidase IV: A Novel Approach for the Prevention and Treatment of Type 2 Diabetes?”, Expert Opin. Investig. Drugs, vol. 13(9) pp. 1091-1102, 2004.
K. Augustyns et al., “Dipeptidyl Peptidase IV Inhibitors as New Therapeutic Agents for the Treatment of Type 2 Diabetes”, Expert Opin. Ther. Patents, vol. 13(4), pp. 499-510, 2003.
Novartis AG: WO0034241, “Novel N-substituted-2-Cyanopyrrolidines as Potent Inhibitors of Dipeptidyl Peptidase IV in the Treatment of Non-Insulin-Dependent Diabetes Mellitus”, Exp. Opin. Ther. Patents, vol. 10(12) , pp. 1937-1942, 2000.
Biftu Tesfaye
Feng Danqing Dennis
Liang Gui-Bai
Qian Xiaoxia
Weber Ann E.
Durette Philippe L.
Kifle Bruck
Merck & Co. , Inc.
Winokur Melvin
LandOfFree
Beta-amino heterocyclic dipeptidyl peptidase inhibitors for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Beta-amino heterocyclic dipeptidyl peptidase inhibitors for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Beta-amino heterocyclic dipeptidyl peptidase inhibitors for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3591892